[A24-86] Durvalumab (first-line in combination with carboplatin and paclitaxel, maintenance in combination with olaparib; endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2024
Project no.:
A24-86
Commission:
Commission awarded on 22.08.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with primary advanced or recurrent mismatch repair proficient endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab in combination with olaparib
- Patients with newly diagnosed disease: hint of considerable added benefit
- Patients with recurrent disease: hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-86
| Project no. | Title | Status |
|---|---|---|
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-27 | Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-30 | Tremelimumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-29 | Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-31 | Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-87 | Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-87 | Durvalumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |